Summary: In an unblinded 6-month multicentre randomized controlled trial of 149 adults with type 2 diabetes in Germany, adding the Vitadio self-management app to standard care lowered HbA1c by an adjusted mean difference of 0.53% versus standard care alone (95% CI -0.82 to -0.24; P<.001; Cohen d 0.67). Modest between-group benefits were also seen for weight, BMI, systolic blood pressure, diabetes-related distress, and self-care behaviours.
PICO Summary
| Element | Detail |
|---|---|
| Population | 149 adults (aged 18+) with type 2 diabetes; 2-arm, unblinded, multicentre RCT at two centres in Germany; 61% male; 19% dropout at 6 months; intention-to-treat analysis. |
| Intervention | Standard diabetes care plus the Vitadio mobile app (educational modules, motivational messages, peer support, personalised goal setting, health monitoring) for 6 months (n=73). |
| Comparison | Standard diabetes care alone (routine clinical care and consultations) (n=76). |
| Outcome | Primary: HbA1c change at 6 months. Both arms fell (intervention -0.8%, SD 0.9, P<.001; control -0.3%, SD 0.7, P=.001); adjusted between-group mean difference -0.53% favouring the app (95% CI -0.82 to -0.24; P<.001; Cohen d 0.67, 95% CI 0.33-1.00). Secondary, significant in favour of the app: weight (P=.002), BMI (P=.001), systolic blood pressure (P<.03), diabetes-related distress (P<.03), and general diet, specific diet and exercise self-care (P<.001 to P<.03). No absolute risk reduction or NNT applies to these continuous outcomes. |
Vitadio app for type 2 diabetes
RCT · type 2 diabetes · 6 months
Adding the Vitadio app to standard care lowered HbA1c by an adjusted 0.53% over 6 months, a clinically meaningful gain, but the unblinded design and manufacturer involvement temper certainty.
Expert Commentary
This trial offers a positive but cautious signal that structured app-based self-management can add to standard care in type 2 diabetes. The adjusted HbA1c advantage of roughly half a percentage point is clinically meaningful and was accompanied by consistent secondary gains in weight, blood pressure, distress, and self-care, which lends internal coherence to the result. The headline finding is best read as supportive rather than definitive, because two design features temper enthusiasm. First, the trial was unblinded, so participants knew their allocation; in a behavioural intervention measured partly through self-reported diet, exercise, and distress, expectation effects could inflate the apparent benefit. Second, four of the six authors are employed by the app manufacturer, and that sponsorship warrants the usual caution about reporting and analytic choices, even where the primary outcome is an objective laboratory value. The 19% dropout and modest sample further limit precision. Can I use this with my patients? Yes, for motivated adults with type 2 diabetes who are comfortable with smartphones and want extra self-management support alongside, not instead of, usual care; it should not be presented as a substitute for medication titration. Independent replication with blinded outcome adjudication and longer follow-up would strengthen confidence in durability. Clinicians should frame this as a helpful adjunct, weigh cost and access, and reassess glycaemic control on standard schedules rather than relying on app metrics alone.
References
Bretschneider MP, Kolasińska AB, Šomvárska L, Klásek J, Mareš J, Schwarz PE. Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial. J Med Internet Res. 2025;27:e68648. doi:10.2196/68648